Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research

Critical Reviews in Oncology/Hematology

Volumn 96, Issue 1, 2015, Pages 113-128

  Gadducci, Angiolo ^a   Lanfredini, Nora ^a   Sergiampietri, Claudia ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Bevacizumab; Cervical cancer; Endometrial cancer; Epithelial ovarian cancer; Molecular signatures; Nintedanib; Pazopanib; Trebanabib

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IXABEPILONE; LAPATINIB; NINTEDANIB; OLAPARIB; PACLITAXEL; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TOPOTECAN; TREBANANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; HYBRID PROTEIN; VASCULOTROPIN A;

ALLERGIC REACTION; AMINOTRANSFERASE BLOOD LEVEL; ANTIANGIOGENIC ACTIVITY; ARTERIAL THROMBOEMBOLISM; ARTERY RUPTURE; ARTERY THROMBOSIS; BLEEDING; BLOOD TOXICITY; BRACHYTHERAPY; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CHEMORADIOTHERAPY; CYTOREDUCTIVE SURGERY; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG INTERMITTENT THERAPY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; ENDOMETRIUM CANCER; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE GENITAL TRACT CANCER; FISTULA; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPOKALEMIA; LIVER TOXICITY; LUNG EMBOLISM; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; OPTIMAL DRUG DOSE; OVARY CARCINOMA; PAIN; PERIPHERAL EDEMA; PROTEINURIA; REVIEW; SENSORY NEUROPATHY; SEX CORD TUMOR; SIDE EFFECT; THROMBOSIS; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; URINARY TRACT FISTULA; UTERINE CERVIX CANCER; UTERUS SARCOMA; VASCULAR ENDOTHELIUM; VEIN THROMBOSIS; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT; ANTAGONISTS AND INHIBITORS; FEMALE; GENITAL NEOPLASMS, FEMALE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; TUMOR RECURRENCE;

ANGIOGENESIS INHIBITORS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84942197504     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.05.009     Document Type: Review

References (123)

1. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 2007, 6:273-286.
2. Zetter B.R. The scientific contributions of M. Judah Folkman to cancer research. Nat Rev Cancer 2008, 8(August (8)):647-654.
3. Al-Husein B., Abdalla M., Trepte M., Deremer D.L., Somanath P.R. Antiangiogenic therapy for cancer: an update. Pharmacotherapy 2012, 32:1095-1111.
4. Escudier B., Albiges L., Sonpavde G. Optimal management of metastatic renal cell carcinoma: current status. Drugs 2013, 73:427-438.
5. Gadducci A., Sergiampietri C., Guiggi I. Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option. Gynecol Endocrinol 2013, 29:811-816.
6. Giampieri R., Scartozzi M., Del Prete M., et al. The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer. Cancer Treat Rev 2014, 40:934-941.
7. Daly S., Kubasiak J.C., Rinewalt D., et al. Circulating angiogenesis biomarkers are associated with disease progression in lung adenocarcinoma. Ann Thorac Surg 2014, 98:1968-1975.
8. de Haas S., Delmar P., Bansal A.T., et al. Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy. Angiogenesis 2014, 17:909-920.
9. Aravantinos G., Pectasides D. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review. J Ovarian Res 2014, 7(May):57.
10. Tewari K.S., Monk B.J. New strategies in cervical cancer: from angiogenesis blockade to immunotherapy. Clin Cancer Res 2014, 20:5349-5358.
11. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1216.
12. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005, 69(Suppl. 3):4-10.
13. Ferrara N., Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989, 161:851-858.
14. Woolard J., Bevan H.S., Harper S.J., Bates D.O. Molecular diversity of VEGF-A as a regulator of its biological activity. Microcirculation 2009, 16:572-592.
15. Brown L.F., Berse B., Jackman R.W., et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995, 26:86-91.
16. Brown L.F., Berse B., Jackman R.W., et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993, 53:4727-4735.
17. Guidi A.J., Abu-Jawdeh G., Tognazzi K., Dvorak H.F., Brown L.F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer 1996, 7:454-460.
18. Wimberger P., Chebouti I., Kasimir-Bauer S., et al. Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance. Gynecol Oncol 2014, 133:467-472.
19. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3:391-400.
20. Domblides C., Gross-Goupil M., Quivy A., Ravaud A. Emerging antiangiogenics for renal cancer. Expert Opin Emerg Drugs 2013, 18:495-511.
21. Partridge A.H., Rumble R.B., Carey L.A., et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2014, 32:3307-3329.
22. Snee M. Bevacizumab in non-small cell lung cancer: an overview of practice in the era of molecular testing. Clin Oncol (R Coll Radiol) 2014, 26:468-472.
23. Holash J., Davis S., Papadopoulos N., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002, 99:11393-11398.
24. Ciombor K.K., Berlin J. Aflibercept - a decoy VEGF receptor. Curr Oncol Rep 2014, 16:368.
25. Macarulla T., Sauri T., Tabernero J. Evaluation of aflibercept in the treatment of metastatic colorectal cancer. Expert Opin Biol Ther 2014, 14:1493-1505.
26. Allen J.W., Moon J., Redman M., et al. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 2014, 32:2463-2470.
27. Chen H., Modiano M.R., Neal J.W., et al. A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. Br J Cancer 2014, 110:602-608.
28. Tannock I.F., Fizazi K., Ivanov S., et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol 2013, 14:760-768.
29. Fernando N.T., Koch M., Rothrock C., et al. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res 2008, 14:2210-2219.
30. Timke C., Zieher H., Roth A., et al. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res 2008, 14:1529-1539.
31. Ionescu C., Berindan-Neagoe I., Burz C., et al. The clinical implications of platelet derived growth factor B, vascular endothelial growth factor and basic fibroblast growth factor in colorectal cancer. J BUON 2011, 16:274-276.
32. Brunckhorst M.K., Xu Y., Lu R., Yu Q. Angiopoietins promote ovarian cancer progression by establishing a procancer microenvironment. Am J Pathol 2014, 184:2285-2296.
33. Schutz F.A., Choueiri T.K., Sternberg C.N. Pazopanib. Clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol 2011, 77:163-171.
34. Bellmunt J., Puente J., Garcia de Muro J., Lainez N., Rodríguez C., Duran I. SEOM clinical guidelines for the treatment of renal cell carcinoma. Clin Transl Oncol 2014, 16:1043-1050.
35. van der Graaf W.T., Blay J.Y., Chawla S.P., et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012, 379:1879-1886.
36. Hilberg F., Roth G.J., Krssak M., et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008, 68:4774-4782.
37. Reck M., Heigener D., Reinmuth N. Nintedanib for the treatment of patients with advanced non-small-cell lung cancer. Expert Rev Clin Pharmacol 2014, 7:579-590.
38. Capdevila J., Carrato A., Tabernero J., Grande E. What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?. Crit Rev Oncol Hematol 2014, 92:83-106.
39. Wedge S.R., Kendrew J., Hennequin L.F., et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005, 65:4389-4400.
40. Laurie S.A., Solomon B.J., Seymour L., et al. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. Eur J Cancer 2014, 50:706-712.
41. Judson I., Scurr M., Gardner K., et al. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma. Clin Cancer Res 2014, 20:3603-3612.
42. Batchelor T.T., Mulholland P., Neyns B., et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 2013, 31:3212-3218.
43. Chow L.Q., Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007, 25:884-896.
44. Hansson E.K., Ma G., Amantea M.A., et al. PKPD modeling of predictors for adverse effects and overall survival in sunitinib-treated patients with GIST. CPT Pharmacomet Syst Pharmacol 2013, 2(December):e85.
45. Karampelas I.N., Syrigos K.N., Saif M.W. Targeted agents in treatment of neuroendocrine tumors of pancreas. JOP 2014, 15:351-353.
46. Wilhelm S., Carter C., Lynch M., et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006, 5:835-844.
47. Bruix J., Sherman M. American association for the study of liver diseases: management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022.
48. Falcon B.L., Hashizume H., Koumoutsakos P., et al. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 2009, 175:2159-2170.
49. Papapetropoulos A., Fulton D., Mahboubi K., et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 2000, 275:9102-9105.
50. Coxon A., Bready J., Min H., et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 2010, 9:2641-2651.
51. Peeters M., Strickland A.H., Lichinitser M., et al. A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. Br J Cancer 2013, 108:503-511.
52. Gourley C. Trebananib: an alternative anti-angiogenic strategy. Lancet Oncol 2014, 15:776-777.
53. Burger R.A., Sill M.W., Monk B.J., Greer B.E., Sorosky J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007, 25:5165-5171.
54. Cannistra S.A., Matulonis U.A., Penson R.T., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007, 25:5180-5186.
55. Burger R.A., Brady M.F., Bookman M.A., et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011, 365:2473-2483.
56. Perren T.J., Swart A.M., Pfisterer J., et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011, 365:2484-2496.
57. Secord A.A., Nixon A.B., Hurwitz H.I. The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer. Gynecol Oncol 2014, 135:349-358.
58. Backen A., Renehan A.G., Clamp A.R., et al. The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer. Clin Cancer Res 2014, 20:4549-4558.
59. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
60. Winterhoff B.J.N., Kommoss S., Oberg A.L., et al. Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer. J Clin Oncol 2014, 32(5s). [suppl; abstr. 5509].
61. Gourley C., McCavigan A., Perren T., et al. Molecular subgroup of high-grade serous ovarian cancer/HGSOC) as a predictor of outcome following bevacizumab. J Clin Oncol 2014, 32(5s). [suppl; abstr. 5502].
62. Aghajanian C., Blank S.V., Goff B.A., et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012, 30:2039-2045.
63. Pujade-Lauraine E., Hilpert F., Weber B., et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014, 32:1302-1308.
64. Tao X., Sood A.K., Deavers M.T., et al. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol 2009, 114:431-436.
65. Barrena Medel N.I., Herzog T.J., Wright J.D., Lewin S.N. Neoadjuvant bevacizumab in a granulosa cell tumor of the ovary: a case report. Anticancer Res 2010, 30:4767-4768.
66. Brown J., Brady W.E., Schink J., et al. Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group. Cancer 2014, 120:344-351.
67. Monk B.J., Sill M.W., Burger R.A., Gray H.J., Buekers T.E., Roman L.D., Phase I.I. trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2009, 27:1069-1074.
68. Tewari K.S., Sill M.W., Long H.J., et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014, 370:734-743.
69. Schefter T., Winter K., Kwon J.S., et al. RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. Int J Radiat Oncol Biol Phys 2014, 88:101-105.
70. Aghajanian C., Sill M.W., Darcy K.M., et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2011, 29:2259-2265.
71. Simpkins F., Drake R., Escobar P.F., Nutter B., Rasool N., Rose P.G. A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA). Gynecol Oncol 2014, pii: S0090-8258(14)01559-5 [Epub ahead of print]. 10.1016/j.ygyno.2014.12.004.
72. Hensley M.L., Miller A., O'Malley D.M., et al. A randomized phase III trial of gemcitabine+docetaxel+bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol 2015, 33:1180-1185.
73. Tew W.P., Colombo N., Ray-Coquard I., et al. Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study. Cancer 2014, 120:335-343.
74. Coleman R.L., Duska L.R., Ramirez P.T., et al. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol 2011, 12:1109-1117.
75. Colombo N., Mangili G., Mammoliti S., et al. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol Oncol 2012, 125:42-47.
76. Gotlieb W.H., Amant F., Advani S., et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advancedovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2012, 13:154-162.
77. Coleman R.L., Sill M.W., Lankes H.A., et al. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2012, 127:538-543.
78. Mackay H.J., Buckanovich R.J., Hirte H., et al. A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. Gynecol Oncol 2012, 125:136-140.
79. Friedlander M., Hancock K.C., Rischin D., et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010, 119:32-37.
80. Eichbaum M., Mayer C., Eickhoff R., et al. The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer. BMC Cancer 2011, 11:453.
81. du Bois A., Floquet A., Kim J.W., et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol 2014, 32:3374-3382.
82. Monk B.J., Mas Lopez L., Zarba J.J., et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 2010, 283:562-569.
83. Gadducci A., Guerrieri M.E. Pharmacological treatment of uterine leiomyosaromas. Expert Opinion. Pharmacotherapy 2014, 22:1-12. Epub ahead of print.
84. Ledermann J.A., Hackshaw A., Kaye S., et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011, 29:3798-3804.
85. du Bois A., Kristensen G., Ray-Coquard I., et al. AGO-OVAR 12: a randomized placebo-controlled GCIG/ENGOT-intergroup phase III trial of standard frontline chemotherapy +/- nintedanib for advanced ovarian cancer. Int J Gynecol Cancer 2013, 23(Suppl. 1). LBA1.
86. Wong H.H., Parkinson C., Ledermann J.A., et al. Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanibin a patient with a germline BRCA1 mutation. Gynecol Oncol Case Rep 2012, 3:7-10.
87. Dizon D.S., Sill M.W., Schilder J.M., et al. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 2014, 135:441-445.
88. Meng X., Dizon D.S., Yang S., et al. Strategies for molecularly enhanced chemotherapy to achieve synthetic lethality in endometrial tumors with mutant p53. Obstet Gynecol Int 2013, 2013:828165.
89. Matulonis U.A., Berlin S., Ivy P., et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009, 27:5601-5606.
90. Raja F.A., Griffin C.L., Qian W., et al. Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer. Br J Cancer 2011, 105:884-889.
91. Ledermann T.J.P., Raja J.A., Embleton F.A.A., et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial. Eur J Cancer 2013, 49(Suppl. 3):LBA10.
92. Liu J.F., Barry W.T., Birrer M., et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014, 15:1207-1214.
93. Parmar M.K., Ledermann J.A., Colombo N., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003, 361:2099-2106.
94. Pfisterer J., Plante M., Vergote I., et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006, 24:4699-4707.
95. Pujade-Lauraine E., Wagner U., Aavall-Lundqvist E., et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010, 28:3323-3329.
96. Biagi J.J., Oza A.M., Chalchal H.I., et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol 2011, 22:335-340.
97. Baumann K.H., du Bois A., Meier W., et al. A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Ann Oncol 2012, 23:2265-2271.
98. Campos S.M., Penson R.T., Matulonis U., et al. A phase II trial of sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol 2013, 128:215-220.
99. Leone Roberti Maggiore U., Valenzano Menada M., Venturini P.L., Ferrero S. The potential of sunitinib as a therapy in ovarian cancer. Expert Opin Investig Drugs 2013, 22:1671-1686.
100. Bauerschlag D.O., Hilpert F., Meier W., et al. Evaluation of potentially predictive markers for anti-angiogenic therapy with sunitinib in recurrent ovarian cancer patients. Transl Oncol 2013, 6:305-310.
101. Rauh-Hain J.A., Penson R.T. Potential benefit of sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma. Int J Gynecol Cancer 2008, 18:934-936.
102. Anglesio M.S., George J., Kulbe H., et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res 2011, 17:2538-2548.
103. Sowter H.M., Raval R.R., Moore J.W., Ratcliffe P.J., Harris A.L. Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res 2003, 63:6130-6134.
104. Mackay H.J., Tinker A., Winquist E., et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol 2010, 116:163-167.
105. Castonguay V., Lheureux S., Welch S., et al. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia. Gynecol Oncol 2014, 134:274-280.
106. Hensley M.L., Sill M.W., Scribner D.R., et al. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol 2009, 115:460-465.
107. Matei D., Sill M.W., Lankes H.A., et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 2011, 29:69-75.
108. Bodnar L., Górnas M., Szczylik C. Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. Gynecol Oncol 2011, 123:33-36.
109. Welch S.A., Hirte H.W., Elit L., et al. Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium. Int J Gynecol Cancer 2010, 20:787-793.
110. Ramasubbaiah R., Perkins S.M., Schilder J., et al. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Gynecol Oncol 2011, 123:499-504.
111. Herzog T.J., Scambia G., Kim B.G., et al. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. Gynecol Oncol 2013, 130:25-30.
112. Matsumura N., Mandai M., Okamoto T., et al. Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. Cancer Sci 2010, 101:2658-2663.
113. Koshiyama M., Matsumura N., Baba T., Yamaguchi K., Yoshioka Y., Konishi I. Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib. Cancer Biol Ther 2014, 15:22-25.
114. Nimeiri H.S., Oza A.M., Morgan R.J., et al. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago PMH, and California Phase II Consortia. Gynecol Oncol 2010, 117:37-40.
115. Herbst R.S., Hong D., Chap L., et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009, 27:3557-3565.
116. Mita A.C., Takimoto C.H., Mita M., et al. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 2010, 16:3044-3056.
117. Karlan B.Y., Oza A.M., Richardson G.E., et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 2012, 30:362-371.
118. Lu J.F., Rasmussen E., Karlan B.Y., et al. Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. Cancer Chemother Pharmacol 2012, 69:1135-1144.
119. Monk B.J., Poveda A., Vergote I., et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014, 15:799-808.
120. Monk B.J., Minion L., Lambrechts S., Vergote I.B., Devoogdt N., Karlan B.Y. Incidence and management of edema associated with trebananib (AMG 386). Gynecol Oncol 2013, 130:636-641.
121. Eskander R.N., Tewari K.S. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma - mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol 2014, 132:496-505.
122. Robson E.J., Ghatage P. AMG 386 profile of a novel angiopoietin antagonist in patients with ovarian cancer. Expert Opin Investig Drugs 2011, 20:297-304.
123. Oliver K.E., McGuire W.P. Ovarian cancer and antiangiogenic therapy: caveat emptor. Clin Oncol 2014, 32:3353-3356.